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Abstract 
A mathematical model relating the activity of adenylate cyclase (AC) with concentrations of stimulators, equilibrium dissociation 
constants, specific activity and efficacies of AC depending on the states of its binding sites has been developed and used for analysis of 
the data on activation of AC of bovine adrenal cortex plasma membranes presented in (De Foresta et al. (1987) FEBS Lett. 216, 
107-112). Equilibrium dissociation constants, xh and x I, corresponding to high- and low-affinity forskolin-binding sites were estimated 
to be 0.37 and 17 /xM; these constants characterize forskolin's potency more adequately than does EDs0, the concentration eliciting 
half-asymptotic a tivity of AC. Corticotropin does not affect the affinity of AC for tbrskolin whereas fluoride increases this affinity, thus 
augmenting forskolin's potency. Hormone receptor of adenylate cyclase of bovine adrenal cortex has been suggested to have two or more 
binding sites for corticotropin. Some unidentified factor(s) may be responsible for the differences found in adenylate cyclase activity in 
different experiments carried out under similar conditions. The model applied for the analysis may be thought o be the best means for the 
moment o relate dose-response d pendencies with what is known or can be hypothesized about the mechanisms underlying activation of 
adenylate cyclase. 
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1. Introduction 
Adenylate cyclase, the enzyme converting ATP into 
cyclic AMP (cAMP) [1,2] is considered to be composed of 
three types of structural components [1]: receptors for a 
variety of hormones, neurotransmitters o  other regulatory 
molecules [1-8], stimulatory (G~) and inhibitory (G i) gua- 
nine nucleotide-binding proteins (G-proteins) mediating 
the stimulation or inhibition [9] and catalytic omponent, 
catalytic (sub)unit or catalyst [1]. Alternately, in G- 
protein-centred reviews, adenylate cyclase (or more pre- 
cisely, its catalyst) is considered as an effector in a trans- 
membrane signal transduction system, G-protein playing 
the role of a transducer [9-11]. cAMP synthesis can be 
stimulated beyond the receptors by diterpene forskolin 
[3-5], by fluoride acting via G~ [12-15] or affected by 
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other agents. Adenylate cyclase (i.e., the 3-component 
complex) has been shown to have two forskolin-binding 
sites, the low-affinity site being associated with the cata- 
lyst, and the high-affinity one being attributed to the 
activated complex of the catalyst with G-protein [16,17]. 
Although forskolin interacts directly with the catalyst 
[18,19], G-protein is necessary for the full expression of 
the effect of forskolin [20,21]. For understanding the pro- 
cesses of control of activity of the cyclase, of all available 
data on its stimulation or inhibition those providing more 
details are of major interest. 
In de Foresta and co-authors' article [6] dose-response 
curves for both forskolin and hormone are presented as 
well as curves for combined effects of those agents and for 
forskolin and fluoride; divergence is demonstrated between 
combined effect of forskolin and hormone and that of 
forskolin and fluoride; difference in dose-response curves 
for forskolin and for hormone can be seen: the curve for 
forskolin extends over a wider range of concentrations 
than that for hormone. 
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A simple mathematical model has been developed to 
relate the dose-response curves with known or putative 
properties of the cyclase and the agents affecting its activ- 
ity (see Appendix). The subject of this article is to analyze 
and interpret the results of the quoted work [6] in terms of 
the model with the view to elucidate the mechanisms 
underlying control of activity of adenylate cyclase. 
2. Methods and model 
Materials and methods used are described in [6]. Briefly, 
bovine adrenal cortex plasma membranes were prepared 
by homogenizing the cortex essentially as in [22] as modi- 
fied in [6]. The preparation i cluded the preparation of a 
mitochondrial-lysosomal fr ction, followed by a centrif- 
ugation at equilibrium in a discontinuous sucrose gradient. 
Adenylate cyclase activity was determined at pH 7.5 and 
30°C [6]. The cAMP formed was determined as described 
in [23] using an Amersham assay kit. 
The model is based on the following: (1) interactions 
between hormone and its receptor and between forskolin 
and adenylate cyclase are reversible [3,4]; (2) affinity of 
hormone receptor for hormone and those of forskolin-bind- 
ing sites for forskolin either (i) remain unaltered irrespec- 
tive of the states of other sites (free or occupied) or the 
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Fig. 1. Schematic representation f interactions between adenylate cy- 
clase complex (AC) and forskolin (F). Possible states of the complex with 
regard to the states of its hormone receptor (unshaded figures correspond- 
ing to inactive states of hormone receptor, the shaded ones, to active 
states) and occupancy of its forskolin-binding sites are designated as 
00,...,21. Forskolin-binding sites are characterized by equilibrium dissoci- 
ation constants, the above states of the cyclase, by their efficacies (see 
text for details). 
receptor (inactive or active) or (ii) are altered as a result of 
interaction(s) of forskolin or hormone with other site(s) or 
the receptor; (3) adenylate cyclase complex is supposed to 
assume any of several fixed states (and to exhibit any of 
several fixed efficacies) depending on the states of its 
hormone receptor (either inactive or active) and its 
forskolin-binding sites (either free or occupied) (Fig. 1); 
(4) the total observable activity is comprised of the activi- 
ties of all the complexes of the cyclase in all the states, the 
contribution of the complexes in each state being propor- 
tional to the efficacy of the complex and the number of 
complexes in this state depending on the concentrations of 
stimulators. 
Under these assumptions, modelling of dose-response 
curves is a matter of technique, even if complicated. 
Relative concentrations of adenylate cyclase complexes in 
each state (Fig. 1) can be found in principle from the 
system of equilibrium equations based on the Law of Mass 
Action. This approach, however, is impracticable because 
of a number of possible states. In addition, the alternatives 
in statement (2) mean that several models are possible. The 
simplest case corresponding to the alternative (i) is devel- 
oped in the Appendix. 
According to the model (see Eq. (A-9) and Eqs. (A-3)- 
(A-8)), the activity of adenylate cyclase depends on the 
concentration f forskolin, x, and that of hormone or other 
agent, y, as follows: 
XhX, (xh+x~)x 
a = c~ ( X + Xhl(  X + x , l  eoo + ( X + xh l (  x + x , l  elO 
1 + (X+Xh) (X+Xl )e20  (1 -P r )  
X~Xl (xh+xl)x 
+~ (x+xh l (x+x, )  eo, + (x+x~)(x+x, )e , l  
+ (x+xh) (x+x, )e2 ,  P~ (1) 
where a is specific activity of the cyclase; x h and x~ are 
equilibrium dissociation constants corresponding to high- 
and low-affinity forskolin-binding sites; e00 >_ 0 ........ e2~ 
> 0 are relative efficacies of adenylate cyclase complex 
corresponding to the states of forskolin-binding sites and 
that of the receptor, the numerical subscripts, 0, 1 and 2 
referring to no one, any one and both forskolin-binding 
sites occupied (the first subscript), 0 and 1 referring to 
inactive and active states of the receptor (the second one); 
Pr is the probability for hormone receptor to be active (i.e., 
to be able to affect the state of the catalyst) which in case 
of single hormone-binding site is determined by 
Y 
P~ (2) 
Y +Yr 
where Yr is equilibrium dissociation constant. 
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For x = 0 Eq. (I) is reduced to 1-agent model 
A = ole0o(l - Pr) + C~eo~ Pr (3) 
which can be applied to the activation of the cyclase by 
hormone alone; Pr in the simplest case is determined by 
(2). Similarly, y = 0 in Eq. (1) yields 1-agent 2-binding- 
sites model 
X h X 1 
A = ( + x . ) (  + 
x 2 
°~e2° ( x q- Xh)  ( X q- Xl )  
(Xh q-Xl)X 
+ °~e'° (x  + Xh) (x  + X,) 
+ 
(4) 
which is applicable to the cyclase activation by forskolin 
alone. 
Model fitting to the experimental data was carried out 
by the method of least squares using a special computer 
program (Ju~ka, A., unpublished ata). Analysis of vari- 
ance (Fisher's F-criterion) [24] was used to test the good- 
ness-of-fit of the model as well as to verify the homogene- 
ity of two sets of experimental data. 
3. Model fitting and data analysis 
There is not much sense in fitting a model with 9 
unknown parameters (such as model (1)) to a set of 
experimental data based on 8 or less independent measure- 
ments (corresponding to 8 or less fixed concentrations of
an activator; see Figs. 1 and 2). Eq. (4), however, has only 
5 independent parameters and can be applied to a set of 
data on activation of adenylate cyclase by forskolin alone 
(Fig. 2, left, lower solid curve). While applying the model, 
one of the relative efficacies, e00, was taken for reference; 
it was assumed that e00 = 1; other parameters have been 
estimated as a result of fitting of this model to the data and 
presented in Table 1. 
Application of analysis of variance to the model and the 
data results in F-ratio, 
F = 2.4406 < 4.0662 = F(0.05 ;3,8) 
where F(0.05;3,8) is Fisher's critical value for 0.05 confi- 
dence level and 3 and 8 degrees of freedom, i.e., number 
of independent measurements (i.e., measurements at differ- 
ent fixed concentrations of stimulators) minus number of 
the parameters and total number of measurements minus 
number of independent measurements. On the basis of the 
above inequation the model has been assumed to be in 
agreement with the data. However, this model deviates 
from data points presented on Fig. 3, left (lower dashed 
curve and corresponding data points) for similar experi- 
ment. In these experiments two different preparations of 
the plasma membranes were used (Fig. 1, left, correspond- 
ing to preparation A, Fig. 3, to B), therefore, while analyz- 
ing these data two possibilities had to be considered: (1) 
the results obtained on A and B preparations are signifi- 
cantly different, and (2) the difference is statistically non- 
significant. By analysis of variance significant difference 
between the two sets of data has been found, and because 
of that fitting of the model to these data sets was carried 
out separately, assuming parameter c~ to be different for 
each set. 
It can be seen (Fig. 3, left and right) that several 
combinations of concentrations of stimulators are repre- 
sented twice, both on the curves for a range of concentra- 
tions of forskolin and on the ones for corticotropin (e.g., 0 
concentrations of both stimulators). The activity of the 
cyclase of the same preparation was considered to be 
Table 1 
Parameters of models (1) and (7) estimated a by their fitting to experimental data obtained on three plasma membrane preparations (A, B and C) 
Parameter Symbol Value Dimension 
A B C 
Specific activity of the cyclase 
Equil ibrium dissociation constant 
Relative efficacy 
Efficacy enhancement factor 
Potentiation factor 
a 14.9 
x h 0.368 
x I 16.7 
b 
eto 4.26 
e2o 11.1 
eo I
eli 14.3 
e21 19.2 
EO 
~2 
/3 
12.9 14.9 pmol /min  per mg protein 
0.368 1.41 #M 
16.7 16.7 ktM 
356 - nM 
4.26 4.26 dimensionless 
11.1 7.98 dimensionless 
7.92 - dimensionless 
12.1 - dimensionless 
14.6 - dimensionless 
7.51 6.87 dimensionless 
1.55 1.41 dimensionless 
1.09 1.21 dimensionless 
0.09 0.09 dimensionless 
a e0o has been assumed to be equal to 1. 
b Not determined. 
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Fig. 2. Dependencies of activity of adenylate cyclase of bovine adrenal cortex plasma membranes obtained with preparations A (left), B and C (right) on 
concentration of forskolin applied alone (O, A and O, lower solid curves) or in presence of 56 nM ACTH(1-24) (left, O, upper solid curve) or 10 mM 
NaF (right, • and &, upper solid curves). The curves correspond to Eq. (4) (the lower ones), Eq. (1) (left, solid and dashed ones) and Eq. (7) (right, upper 
solid ones) whose parameters are presented in Table 1. (Right) The dotted curve corresponds to model (7) with /3 = 1; the dashed broken line connects the 
means of data of experiment 2 carried out with preparation B; the bars correspond to S.E. of more than two (three or four) determinations. 
independent of any factors other than stimulators of given 
concentrations. This allowed to consider all the measure- 
ments corresponding tothe same combination as replicates 
of one independent measurement and to take data points 
corresponding to the same combination from one curve 
and plot them additionally on the other and vice versa and 
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Fig. 3. Dependencies of activity of adenylate cyclase (preparation B) on concentration of forskolin (left) or ACTH (right) applied alone (O, lower solid 
curves) or in presence of (left) 8000 nM ACTH (O, upper solid curve); the lower dashed curve corresponds to a determined for preparation A (see Table 
1), the upper dashed one, to ell and e2] determined for preparation A; the dotted curve corresponds to Eq. (9). (Right) The lower solid curve corresponds 
to model (3) with Pr determined by Eq. (5), the middle and the upper solid curves as well as the upper dashed one correspond to model (1) with Pr 
determined by Eq. (5); the dotted one corresponds to Eq. (1) and Pr determined by Eq. (2). The encircled ata points on one side of the Figure correspond 
to the data at the same concentrations of stimulators on the other side and vice versa. The data points marked by the symbols X were excluded from the 
analysis. 
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to use these 'additional' data (encircled ata points on Fig. 
3) for model fitting. Note that the encircled data points are 
close to the corresponding non-encircled ones. 
All the parameters of the model were assumed to be the 
same for all the experimental data obtained on the same 
preparation. To estimate o~ for preparation B, Eq. (3) with 
P, determined by Eq. (2) was applied to the data on 
activation of the cyclase by hormone alone. On the basis of 
Fisher's F-criterion the model fitted could be accepted. 
With c~ estimated above, Eq. (4) fits better to the data 
obtained on the cyclase from preparation B (Fig. 2, right, 
and Fig. 3, left), the number of independent measurement 
not being sufficient o verify the goodness-of-fit. However, 
Eq. (4) taken together with Eq. (3) and considered as one 
model can be applied to the data for forskolin alone and 
hormone alone taken together (considering the data corre- 
sponding to 0 concentrations of the stimulators as data of 
one independent measurement) and analysis of variance 
can be applied to this model and these data. On the basis 
of Fisher's F-criterion the model could be accepted as 
well. 
Eq. (I) with Pr determined by Eq. (2) applied to the 
data on combined effect of hormone and forskolin (Fig. 3, 
right, dotted curve) is rather close to the data points, the 
number of measurements being insufficient again to verify 
the goodness-of-fit. Taken into account the data for 
forskolin alone, the model could  not be accepted. Experi- 
mental data points (see also the points for higher concen- 
tration of forskolin) seem to indicate a sharper bend of the 
curve at high concentrations of hormone than that at low 
concentrations whereas the model curve - a hyperbola - is 
symmetric (if plotted in semilogarithmic s ale), its shape 
being determined, in the last analysis, by the Law of Mass 
Action. No more data are available to justify any modifica- 
tion of the model by introduction of additional parameters 
which would (formally, at least) solve the problem. With 
this in mind, Eq. (2) was substituted (formally) by 
y (y  + 2y~) 
(5) 
which in case of stimulation by hormone alone results in 
y,? y( y + 2y ) 
A =o leoo  + °~eoj . )2 (6)  
( y "~ yr) 2 ( y "[- Vr 
This model fitted to the data is equally acceptable as that 
using Eq. (2): 
F = 1.3974 < 2.8524 = F(0.05;5,16) 
(see Fig. 3, right, lower solid curve). Eq. (5) will be 
substantiated and discussed in more detail in the next 
section. Further parameters estimated are presented in 
Table 1. 
As a result of further fitting (Fig. 3, left, upper solid 
curve) the rest parameters of Eq. (1) with Pr determined 
by Eq. (5) for the combined effect of forskolin and hor- 
mone have been estimated (Table 1). The F-ratio for the 
upper curve, left, and the lower one, right (Fig. 3), taken 
together, 
F = 2.7735 < 3.0491 = F(0.05;3,22), 
and the model has been accepted. 
Model curves (Eq. (1) with Pr determined by (5) and all 
the parameters estimated above) are rather close to experi- 
mental data points corresponding to combined effect of 
hormone and forskolin (Fig. 3, right, middle and upper 
solid curves) without any further fitting; this model fits 
better to the data than that with Pr determined by Eq. (2) 
(compare middle solid curve and dotted one, Fig. 2, right). 
Application of Fisher's F-criterion to the middle solid 
curve, right, and the upper one, left (Fig. 3) yields 
F = 2.6360 < 3.0725 = F(0.05 ;3,21) ; 
on this basis model (1) with Pr determined by Eq. (5) has 
been accepted. 
It can be seen that a few data points deviate consider- 
ably from the upper solid curve (Fig. 3, right). The model 
could be considered consistent with these data only if 
some most deviating data points were excluded from the 
analysis. These deviating data points may indicate to a 
more complicated mechanism of the combined stimulation 
of the cyclase by forskolin and corticotropin than that the 
model is based on, or they may not. To solve this problem, 
more detailed data are necessary. 
Again, as seen from Fig. 2 (left, middle dashed curve), 
model (l) with the values of e~l and e21 estimated above 
does not fit to the data on combined effect of forskolin and 
corticotropin obtained on preparation A. The model was 
fitted to this set of data separately, assuming e~j and e2~ 
to be different from those for set B. As a result, the above 
efficacies for this set have been estimated (Table 1). In this 
case, again, the number of independent measurements is 
not sufficient to verify the goodness-of-fit of the model. 
No more data on this preparation are available. 
There is good reason to apply Eq. (1) to the analysis of 
activation of the cyclase by forskolin and fluoride. Since in 
the work under analysis [6] data on activation of the 
cyclase by fluoride in a range of concentrations are not 
available, Pr in Eq. (1) cannot be determined. However, it 
is clear that for a fixed concentration of fluoride, y = Y0, 
the activity of the cyclase can be considered as a function 
of a single variable, x, concentration of forskolin. This 
function has been shown [25] to be similar to Eq. (4) in 
which the efficacies are changed by some factors indepen- 
dent of x and depending on Y0. 
In the experiments of adenylate cyclase activation by 
forskolin and fluoride, in addition to preparation B, one 
more plasma membrane preparation, C, was used; the data 
of these experiments had to be analyzed separately again. 
In case of preparation C, in absence of activation by 
fluoride, Eq. (4) could be fitted only under assumption that 
one of the dissociation constants, x h, and one of the 
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efficacies e20, are different from those estimated above 
(Table 1: see also Fig. 2, right, lower solid curves labeled 
B and C). 
The data for the combined effect of forskolin and 
fluoride obtained in 2 experiments on preparation B proved 
to be non-homogeneous, so these data had to be analyzed 
separately. Eq. (4) with the above modifications and the 
dissociation constants, xh and x~, remaining the same as 
estimated above could not be fitted to either set of data; its 
shape, however, could be made similar to that which fits 
well to the less scattered ata, but remains shifted along 
the concentration axis (Fig. 2, right, dotted curve). It could 
not be fitted by changing either x h or x~ alone: it was 
necessary to change both x h and x~. For this reason these 
constants were multiplied by a formal parameter,/3, whose 
meaning will be discussed in the next section, to yield 
/32XhX 1 
A = c~e01 e 0 ( x +/3Xh) ( X + /3Xl) 
+ (x 
X 2 
+ ae21 e2 ( x +/3xh)  ( x + f ix , )  (7) 
/3 determining the shift of the curve, e 0, e~ and e 2 being 
the factors altering the efficacies of the cyclase due to its 
association with fluoride, their subscripts referring to the 
number of forskolin molecules associated with the cyclase. 
As a result of fitting of model (7) to the less scattered ata 
(let it be the data of experiment 1) for the combined effect 
of forskolin and fluoride (Fig. 1, right, upper solid curve 
labeled B) its parameters have been estimated (Table 1). 
To verify the goodness-of-fit of the model, the number of 
independent measurements in this case is not sufficient, 
either, still visually the model is quite acceptable. 
Eq. (7) also has been fitted to the data obtained on 
preparation C; the parameters estimated are presented in 
Table 1. Taken separately from Eq. (1), this model can be 
considered to have only 5 independent parameters, o its 
goodness of fit to the data of 8 independent measurements 
could be verified. The F-ratio 
F = 1.0081 < 3.0280 = F(0.05;3,23) ; 
and the model has been accepted. 
Model (7) could not be fitted to the set of more 
scattered ata (of experiment 2) either without a shift 
(/3 = 1) or with a shift (/3 < 1) of the curve along the 
concentration axis. This discrepancy will be discussed in 
more detail in the next section. It should be noted that the 
data for forskolin alone in both experiments are homoge- 
neous (Fig. 2, right); this allowed to pool these data 
together (Fig. 3, left, lower solid curve). 
In summary, model (1) is in agreement with the data of 
8 (of total 10) adenylate cyclase activation experiments 
(total 124 measurements), whereas it does not fit to the 
data of 1 experiment, model curve still being close to the 
data points and deviating considerably from 3 points of 16; 
goodness-of-fit of the model to the data of another experi- 
ment (16 measurements) could not be verified. Model (7) 
is in agreement with the data of 2 (of 3) experiments 
whereas no model has been fitted to the data of 1 experi- 
ment. 
For non-linear models (which is the case), it is ex- 
tremely difficult to determine confidence intervals for the 
parameters estimated. Moreover, in the case of multipa- 
rameter models those intervals are strongly interdependent. 
The subject of the present analysis, however, was to relate 
experimental dose-response curves with the properties of 
cAMP-generating system expressed via the parameters of 
the model rather than determine xact values and confi- 
dence intervals of those parameters. 
4. Discussion 
It can be seen that the first term of Eq. (1) corresponds 
to the contribution of adenylate cyclase which is not 
activated by hormone whereas the second one corresponds 
to that of the cyclase which is activated by hormone to its 
observable activity, the terms in the square brackets corre- 
sponding to the cyclase associated with none, 1, and 2 
molecules of forskolin. 
As follows from Eqs. (4) and (6), for x = 0 and y = 0 
(in absence of any activation) A = a eoo or, keeping in 
mind that e00 has been assumed to be equal to 1, A = c~. 
Thus ce, the parameter which has been defined as specific 
activity of the cyclase is equivalent o its background 
activity. 
For x >> x 1 in Eq. (4), A = ae20, i.e., cte20 is equiva- 
lent to the asymptotic activity of the cyclase when acti- 
vated by forskolin alone. 
Similarly, for y>>yr in (6) A = aeol, i.e., c~e0j is 
equivalent to the asymptotic activity of the cyclase acti- 
vated by hormone in absence of forskolin. 
And finally, for both x >> x 1 and y >> Yr (which means 
Pr = 1 in Eq. (l)) A ~ c~e21, i.e., ole21 is equivalent to the 
asymptotic activity of the cyclase activated by a combina- 
tion of forskolin and hormone. 
The relative efficacies e01, e20 and e21, relate, there- 
fore, the asymptotic activities of the cyclase with its 
background activity, e0~ (e20 or e21) being equal to eol-fold 
(e20-fold or e21-fold) stimulation of adenylate cyclase by 
hormone (forskolin or combination of forskolin and hor- 
mone) over its background activity. 
Such an immediate interpretation as above is not possi- 
ble for el0 or e 11, their role not being observable directly. 
It is clear, however, that these parameters reflect the 
contribution of those molecules of the cyclase which are 
associated with one molecule of forskolin to the observ- 
able activity of the cyclase. 
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It is worth noting the importance of absence of interde- 
pendence between the parameters. Let, e.g., el0 be ex- 
pressed as a combination of other parameters, 
X~ X h 
elo = eoo- -  + e2o- -  (8) 
X h q- X I X h q- X I 
Then substitution of e m in Eq. (4) from (8) yields 
X I X 
A = aeoo- -  + ae2o- -  (9) 
x+x R x+xj  
which is hyperbolic and whose shape for given lower and 
upper levels (determined by e00 and e20, as pointed out 
above) cannot be changed; the curve can only be shifted 
along the axis of concentrations by changing &. It could 
not be fitted to the data on activation of the cyclase by 
forskolin (see Fig. 3, left, dotted curve). It should be noted 
as well that x h and x 1 are different (see Table 1), their 
ratio determining the extent of the curve over a range of 
concentrations, provided that (8) is not true. These con- 
stants characterize forskolin's potency more adequately 
than, e.g., does EDso which is conventionally used for this 
purpose. 
The values of x h and x~ estimated (0.37 and 17 /,M) 
can be compared with those, e.g., for binding sites of rat 
brain membranes (15 nM and 1.1 /,M, respectively) deter- 
mined by centrifugation assay [16] or those for adenylate 
cyclase of rat ovaries (0.76 /~M and 37 p,M) estimated at 
the Institute of Biochemistry, Vilnius, by the same method 
as here [25]. 
As shown above (see Fig. 3, right, dotted curve), Eq. 
(1) with P~ defined by Eq. (2) does not fit to the data on 
the combined effect of corticotropin and forskolin on the 
activity of the cyclase. The model fitted (with Pr defined 
by Eq. (5)) was based on the assumption that the receptor 
has two corticotropin-binding sites, both sites being identi- 
cal (to assume those sites being different would involve 
introducing more free (independent) parameters; that would 
make the model loser, less definite). Under this assump- 
tion, there are three possible states of the receptor concern- 
ing its binding sites: (1) both its sites free, (2) one site 
occupied and (3) both sites occupied by molecules of 
corticotropin. The situation can be illustrated by Fig. 1 if 
AC is assumed to symbolize hormone receptor, F, hor- 
mone molecule. To find the probabilities for the receptor 
to be in any of the above states the model developed in 
Appendix for forskolin-binding sites can be used, Substitu- 
tion of y for x and y~ for x, and xl in Eq. (A-6)-Eq. 
(A-8) for Pr = 1 yields: 
y~ 2 Yr Y y 2 
P' ( v + y~)2 , P~ - -  P3  = 
- - (Y  +Yr )  2 '  (Y  +Yr ) "  
In general, the activity of the receptor (i.e., its ability to 
stimulate adenylate cyclase) in the 2nd and 3rd state might 
be different. Such an assumption would, however, involve 
more parameters again, so it has been abandoned. The 
receptor in the 1st state has been assumed to be inactive. 
There remain three possibilities for its activity to be linked 
with its states defined above: it is active when being (i) in 
state 2, (ii) in state 3 and (iii) in state 2 or state 3. This is 
equivalent to three possibilities for Pr in Eq. (3): 
(i) Pr = P2, (ii) Pr = P3 and (iii) P, = P2 + P3 
In case (i) Eq. (3) yields a bell-shaped curve (if plotted in 
semilogarithmic s ale) with a pointed peak. No evidence is 
available on a peak or a decline of activity of the cyclase 
at high concentrations of corticotropin (see Fig. 3, right). 
Thus this possibility has been rejected. It can be seen that 
by assuming Pr = P2/2 + P3 the 2-binding-site model un- 
der analysis is reduced to Eq. (2), i.e., to 1-binding-site 
model. The model which has been accepted was based on 
the assumption (iii), i.e., that 
Pr = P2 + P3 
(see Eq. (5)) which means the receptor being active when 
at least one of its two hormone-binding sites is occupied. 
In other words, binding of another hormone molecule to 
the receptor does not affect its activity. Keeping in mind 
that stimulatory G protein transducing the activation from 
the receptor to the catalyst is a GTPase which is consid- 
ered to act as a switch triggered by the receptor [26], the 
above conclusion seems to be quite reasonable. Indeed, 
having been triggered 'on', the switch is no longer affected 
by the receptor and, consequently, by another hormone 
molecule. As shown above, this two-binding-sites model is 
in agreement with experimental data whereas one- 
binding-site (hyperbolic) model is not. That does not mean 
that no other model can be fitted to the data. Alternative 
models (see, e.g., [27,28] could be tested if more detailed 
data were available. 
In summary, in spite of the apparent complexity of 
model (1) having 9 parameters, there is good reason to 
believe that it is the simplest possible model relating 
dose-response d pendencies with what is known or can be 
hypothesized about the mechanisms of adenylate cyclase 
activation. All the parameters of the model are indispens- 
able; there is no interdependence b tween the parameters. 
The parameters of the model were supposed to be 
useful as quantitative measures of intrinsic properties of 
adenylate cyclase and to be independent of any other 
factors. The difference in the values of c~ for two different 
preparations (see Table 1) does not seem surprising: c~ 
was estimated as the rate of cAMP production per mil- 
ligram of protein rather than per (pico)mol of adenylate 
cyclase; possible difference in the purity of the cyclase in 
different plasma membrane preparations ( ee section Meth- 
ods and model) could account for the difference found; a 
should be better egarded for this reason to characterize a 
preparation and only indirectly adenylate cyclase itself. 
The differences in further parameters, ejj and e21, 
cannot be explained this way; besides, e21 > e2o + e01 for 
preparation A but e2~ < e20 + e0~ for B (see Table 1). That 
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means the combined effect of forskolin and corticotropin 
to be lesser than additive in the second case (as pointed out 
in [6]) but greater than that in the first one. To demonstrate 
the difference, a curve with parameters eL~ and e2~, esti- 
mated for preparation A is plotted on Fig. 3 corresponding 
to B (left, upper dashed curve). Model curves are plotted 
as well for high concentrations of corticotropin (Fig. 2, 
left, upper dashed curve) and forskolin (Fig. 3, right, upper 
dashed curve). Note the tendency of the curves to get away 
from each other for preparation A and to get closer to each 
other for preparation B with the increase of concentration 
of forskolin or corticotropin. 
It should be noted that additivity or non-additivity of 
the effects of two stimulators cannot serve as a criterion 
for sorting out the possible mechanisms of adenylate cy- 
clase activation. As seen from Eqs. (1), (4) and (6), the 
effect of two stimulators, in general, is not additive. That is 
because the most essential element of the system - the 
catalyst - is the same for all the stimulators whatever the 
pathway of activation - via receptors, G-protein or beyond 
these elements. 
Likewise, the concept of synergism useful to charac- 
terize observable ffects of two stimulators turns out to be 
misleading when judging about the mechanisms underly- 
ing those effects. As seen above, different effects (in terms 
of synergism) can be produced by the same mechanism 
which is described by the same model. 
Concerning the differences discussed, the following 
problems arise: (i) do those differences reflect any differ- 
ence in properties of the cyclase used in different experi- 
ments? (in other words, was the cyclase different in differ- 
ent preparations?); if no, (ii) what are the causes of the 
differences found? and (iii) how to relate those differences 
with the model? 
A positive answer to the first question does not seem 
plausible, still ruling out such a possibility would be 
imprudent. Results obtained at the Institute of Biochem- 
istry in Vilnius [25] show that some properties of adenylate 
cyclase from the cells of the same organs - from ovaries 
of intact rats, ovarian malignant cells and ovaries of tu- 
mour-bearing rats - are slightly different. 
As for the possible causes of the differences found, they 
have to be bound up, presumably, with the conditions of 
the experiments: ome unknown factor(s) had to be present 
in one case while being absent in the other or vice versa. 
The model discussed (see Eq. (1)) implies the activity 
of adenylate cyclase to be independent of any factors other 
than concentrations of two stimulators. To take into ac- 
count the unknown factor(s), the model has to be extended 
and include some additional parameter(s) related with the 
unknown factor(s); in such an extended model the parame- 
ters el~ and e21 would remain the same for both prepara- 
tions. 
As shown above, Eq. (1) had to be modified to take into 
account he effect of fluoride on x h and x~, the dissocia- 
tion constants for forskolin (see Eq. (7)). It should be 
reminded that Eq. (1) was based on the assumption, among 
others, that the affinities of forskolin-binding sites for 
forskolin remain unaltered irrespective of interaction(s) of 
other agent(s) with other site(s). For combined effect of 
forskolin and fluoride this assumption proved to be false. 
Decrease of the dissociation constants means increase of 
the affinities of the sites for forskolin and, eventually, 
augmentation forskolin's potency; the formal parameter, 
/3, determining the lowering of the constants, has been 
denoted for this reason as a potentiation factor (see Table 
1). It should be noted that model (7) with /3 4: I (which is 
supposed to be the case) is valid only if al l  the adenylate 
cyclase complexes can be considered to be affected by 
fluoride. For the concentration of NaF used (10 mM) this 
assumption seems to be quite justified (see dose-response 
curves for fluoride, e.g., in [5,12,14]). Indeed, model (7) 
based on this assumption is in agreement with the data of 2 
(of total 3) experiments of combined stimulation of the 
cyclase by fbrskolin and fluoride. However, as mentioned 
above, this model could not be fitted to the data of 
experiment 2. Greater variance is characteristic to the data 
of experiment 2 which suggests possible effect of some 
unknown factor(s) in this experiment. 
In absence of stimulation by forskolin, adenylate cy- 
clase activity is affected by fluoride acting via G-protein, 
the observable effect depending on the concentration of A1, 
Be, or Mn ions [13,14]. Possible variation in the concentra- 
tion of these ions could account for the variance of the 
observable activity of the cyclase and could leave a frac- 
tion of the cyclase with the affinity for forskolin una l te red  
making model (7) invalid in this case. No more data are 
available to support or reject this possibility. It should be 
noted that although model (7) is not supported by the data 
of experiment 2, it cannot be rejected on the basis of these 
data, either. The main assumption of the model - augmen- 
tation of forskolin's potency by fluoride - could be re- 
jected only if model (7) with /3 = I (i.e., with no potentia- 
tion) was in agreement with the data. 
It is of interest hat activity of the cyclase as a function 
of concentration of forskolin for the concentration of fluo- 
ride used has a minimum (see Fig. 2, right); respectively, 
e~ < e0~ for this combination of stimulators whereas e~ 
> e0~ for forskolin and hormone (see Table 1). Similar 
curves with a minimum can be found for other stimulators, 
e.g., for GppNHp [4], for GYlay S [29]. 
5. Conclusions 
(l) All the parameters of the models discussed are 
related with the intrinsic properties of adenylate cyclase; 
there is no interdependence b tween the parameters. 
(2) Equilibrium dissociation constants, xh and x I (0.37 
and 17 /xM), corresponding to high- and low-affinity 
forskolin-binding sites characterize forskolin's potency 
more adequately than does ED~ 0, the concentration elicit- 
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ing half-maximal or, more accurately, half-asymptotic a - 
tivity. 
(3) Corticotropin does not affect the affinity of the 
catalyst for forskolin whereas fluoride increases this affin- 
ity, thus augmenting forskolin's potency. 
(4) There is good reason to believe that hormone recep- 
tor of adenylate cyclase bovine adrenal cortex has two or 
more binding sites for corticotropin. 
(5) Some unidentified factor(s) may be responsible for 
the differences found in adenylate cyclase activity in dif- 
ferent experiments carried out under similar conditions. 
(6) The models discussed may be thought o be the best 
means for the moment o relate dose-response d penden- 
cies with what is known or can be hypothesized about the 
mechanisms underlying activation of adenylate cyclase. 
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Appendix 1 
Assumption (2) with the alternative (i) allows to apply 
the Law of Mass Action to any class of binding sites or the 
receptor separately. E.g., the fraction of occupied high-af- 
finity forskolin-binding sites (which is convenient to be 
considered as the probability for the site to be occupied), 
Ql~, is 
x 
Qh = - -  (A-l)  
x+x h 
where x is concentration of forskolin, x h is equilibrium 
dissociation constant. Obviously, the probability for the 
site to be free, R h, is 
x h 
R,, (A-2) 
X-~ X h 
The probability for adenylate cyclase complex to assume a
concrete state is determined by the probabilities for the 
states of corresponding binding sites and that for hormone 
receptor. If the probability for hormone receptor to be 
active is P~ then the probability for the complex to as- 
sume, e.g., state O0 (see Fig. 1), S00, is 
S0o : Rh Rl(1 - Pr)  
or  
Yh X 1 
So, = (1 - P~) (A-3) 
the subscript h referring to the low affinity site. Similarly, 
S,o = (Qh R, + RhQ,)(I --Pr) 
or 
Si0 : 
and 
x 2 
s2o = ( l - P , )  (A-X) 
(x+xh)(x+x,) 
XhX [ 
So, = P~. (a-6) 
( xh + x~)~ 
S,1 = P~ (A-7) (x+xh)( +x3 
x 2 
$21 = Pr (A -8 )  
(x  h 4-x~)x  
(1 -P r )  (A-4) 
It can be seen that 
Soo + Slo + S2o + Sol + Sll + S21 = 1 
i.e., (back in terms of concentrations) all the partial con- 
centrations of adenylate cyclase in all the possible states 
make the total concentration which is assumed here to be 
equal to 1. All the partial concentrations known, the 
observable activity, in accordance with assumption (4), can 
be expressed as 
A = ot(Sooeoo + Sl0e|0 + $20e20 + S01e01 
+Sl jet l  + $21e21 ) (A-9) 
where a is specific activity of adenylate cyclase, e00 > 0, 
...... e21 > 0 are efficacies of adenylate cyclase complexes 
in states 00 ....... 21, respectively (Fig. 1). Substitution of 
S00 ....... S21 (Eqs. (A-3)-(A-8)) in Eq. (A-9) yields Eq. (1) 
in the main text. 
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